Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Molecular heterogeneity of triple-negative breast cancer and its clinical implications.
Irshad S, Ellis P, Tutt A. Irshad S, et al. Among authors: tutt a. Curr Opin Oncol. 2011 Nov;23(6):566-77. doi: 10.1097/CCO.0b013e32834bf8ae. Curr Opin Oncol. 2011. PMID: 21986848
PURPOSE OF REVIEW: Triple-negative breast cancer (TNBC) is defined by a lack of expression of hormone receptors, oestrogen and progesterone, as well as human epidermal factor receptor 2. ...RECENT FINDINGS: Emerging evidence clearly indicates that TNBC is a heteroge …
PURPOSE OF REVIEW: Triple-negative breast cancer (TNBC) is defined by a lack of expression of hormone receptors, oestrogen and proges …
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Loi S, et al. Among authors: tutt am. J Clin Oncol. 2007 Apr 1;25(10):1239-46. doi: 10.1200/JCO.2006.07.1522. J Clin Oncol. 2007. PMID: 17401012
MATERIALS AND METHODS: We have previously reported a gene expression grade index (GGI), which defines histologic grade based on gene expression profiles. ...Despite tracking a single biologic pathway, these were highly comparable to the previously described luminal …
MATERIALS AND METHODS: We have previously reported a gene expression grade index (GGI), which defines histologic grade based on gene …
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. Loi S, et al. Among authors: tutt am. BMC Genomics. 2008 May 22;9:239. doi: 10.1186/1471-2164-9-239. BMC Genomics. 2008. PMID: 18498629 Free PMC article.
We used gene expression profiling to develop an outcome-based predictor using a training set of 255 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. ...In 112 metastatic breast cancer patients treated with tamoxifen, one of the classifier components s …
We used gene expression profiling to develop an outcome-based predictor using a training set of 255 ER+ BC samples from women treated …
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Cardoso F, et al. Among authors: tutt a. Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. Ann Oncol. 2017. PMID: 28177437 Free PMC article. No abstract available.
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.
Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A. Irshad S, et al. Among authors: a hern rp, tutt a. Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12. Breast Cancer Res Treat. 2014. PMID: 24519386 Clinical Trial.
Contrary to the hypothesis that taxane benefit would be enriched in Tau negative/low patients, the only groups with a suggestion of a reduced event rate in the taxane group were the HER2-positive, Tau positive subgroups. Tau expression was seen to be a progno …
Contrary to the hypothesis that taxane benefit would be enriched in Tau negative/low patients, the only groups with a suggestion of …
Radiobiology of breast cancer.
Tutt A, Yarnold J. Tutt A, et al. Clin Oncol (R Coll Radiol). 2006 Apr;18(3):166-78. doi: 10.1016/j.clon.2005.11.011. Clin Oncol (R Coll Radiol). 2006. PMID: 16605047 Review.
Commentary: much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer.
Tutt A, Ross G. Tutt A, et al. BMJ. 2000 Feb 19;320(7233):478-9. BMJ. 2000. PMID: 10722296 No abstract available.
Patterns of metastasis in women with metachronous contralateral breast cancer.
Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M. Vichapat V, et al. Among authors: tutt a. Br J Cancer. 2012 Jul 10;107(2):221-3. doi: 10.1038/bjc.2012.273. Epub 2012 Jun 26. Br J Cancer. 2012. PMID: 22735901 Free PMC article.
METHODS: A cohort of 8478 women with breast cancer treated at Guy's and St Thomas' NHS Foundation Trust between 1975 and 2006 were studied. ...RESULTS: Women diagnosed with CBC within 5 years had a higher incidence of metastases in all organs compared with UBC. Wome …
METHODS: A cohort of 8478 women with breast cancer treated at Guy's and St Thomas' NHS Foundation Trust between 1975 and 2006 were st …
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.
Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Dubsky P, et al. Among authors: tutt a. Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. Ann Oncol. 2018. PMID: 29045519 Free PMC article. No abstract available.
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Cardoso F, et al. Among authors: tutt a. Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5. Breast. 2017. PMID: 27927580 No abstract available.
216 results
Jump to page
Feedback